Generic Products (November 2017)

Medroxyprogesterone Acetate Injectable Suspension, USPMARKETED BY: Teva Pharmaceuticals

COMPARE TO: Depo-Provera (Pfizer)

INDICATION: Teva has reintroduced the generic equivalent to Depo-Provera contraceptive injection (medroxyprogesterone ace- tate injectable suspension, USP) 150 mg/mL. Medroxyprogesterone acetate injectable suspension is a progestin indicated only for the prevention of pregnancy.

DOSAGE FORM: Injectable suspension: 150 mg/mL

FOR MORE INFORMATION: tevapharm.com

Nitroglycerin

MARKETED BY: Glenmark Pharmaceuticals

COMPARE TO: Nitrostat (Pfizer) INDICATION: The FDA has approved the generic version of Pfizer’s Nitrostat (nitroglycerin) sublingual tablets USP, 0.3 mg, 0.4 mg, and 0.6 mg. Nitroglycerin is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.

DOSAGE FORM: Tablet: 0.3 mg, 0.4 mg, or 0.6 mg

FOR MORE INFORMATION: glenmarkpharma.com

Desonide Ointment, 0.05%MARKETED BY: Glenmark Pharmaceuticals

COMPARE TO: Desonide Ointment, 0.05% (Perrigo)

INDICATION: The FDA has approved the generic version of Perrigo’s Desonide Ointment, 0.5%. Desonide Ointment is indicated for the

relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

DOSAGE FORM: Topical

FOR MORE INFORMATION: glenmarkpharma.com

Hydromorphone Hydrochloride

MARKETED BY: Perrigo

COMPARE TO: Exalgo (Mallinckrodt Pharmaceuticals)

INDICATION: The FDA has approved Perrigo’s AB-rated generic version of Exalgo (hydromorphone HCl) 32 mg extended-release tab- lets. Hydromorphone hydrochloride is indicated for the management

of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period.

DOSAGE FORM: Extended-release tablets: 32 mg

FOR MORE INFORMATION: perrigo.com